Science 37® and AiCure Partner to Enhance Virtual Clinical Trials
LOS ANGELES & NEW YORK, April 30, 2020 — Science 37, the industry leader in virtual clinical trials, and AiCure, a leading artificial intelligence (AI) and advanced data analytics company, have announced a collaboration to support and deliver enhanced technology for virtual trials. As the first endeavor for the new partnership, the two companies will use a virtual or decentralized research model—in which patients participate from home—to evaluate an investigational treatment for major depressive disorder (MDD) in a clinical trial this summer.
The MDD trial will involve 150 adult participants in the United States. Science 37 will recruit, enroll, and support patients using its virtual model and in-house network of investigators and mobile nurses. In addition, Science 37 will deliver eConsent, eSource, ePRO and telemedicine capabilities through its comprehensive clinical trial platform, the industry’s first and only platform purpose-built to support virtual trials. The virtual approach adds an additional layer of privacy for patients, who can remain at home for mental health care, and increased efficiency for researchers, since many common psychiatric assessments—including the Montgomery-Asberg Depression Rating Scale (MADRS) used in this study—can be performed virtually by Science 37 investigators via telemedicine.
AiCure will enhance the quality of data collected and reduce both the time and cost of conducting the trial by providing real-time monitoring of patient dosing and novel insights into patient behavior. AiCure’s proprietary platform will monitor remote dosing adherence and measure digital biomarkers—including facial and vocal expressivity—to evaluate depression in patients. The platform will also enable remote registration, training, and micro-reimbursements to patients for increased patient participation. In addition, there will be real-time access to patient-quality metrics, which allows for quick, data-driven modifications to study requirements and improves the predictability of study timelines.
“Collaborating with AiCure is a unique opportunity to bring deeper and more novel insights to clinical research without participants ever having to leave the comfort of home,” said David Coman, CEO of Science 37. “Combining our comprehensive, integrated platform with AiCure’s unique AI technology will enable sponsors to develop even more meaningful data for their research.”
“Virtual clinical trials offer a huge opportunity for both patients and sponsors by reducing the burden of having participants have to travel on-site, while also reducing the costs and duration of studies,” said Dr. Ed Ikeguchi, CEO of AiCure. “Having the right tools in place can ensure patients remain engaged for the duration of a trial and help sponsors get critical and accurate data throughout.”
The virtual research model has become the standard of clinical research in the current climate given the massive worldwide quarantine measures currently in effect. Considering the interview-based diagnostic tools such as MADRS commonly used in psychiatry, this model is particularly appropriate for depression research. Science 37 has conducted more fully virtual, interventional clinical trials than any other organization.
About Science 37
Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, we provide access to patients who can never be reached by traditional site-based models. We have proven to enroll faster, retain patients at a higher rate, and reach a more representative population. Science 37 has conducted more decentralized, interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses, who are supported by the industry’s most comprehensive, fully integrated, decentralized clinical trial platform. Learn more at Science 37, and follow Science 37 on Twitter, LinkedIn, and Facebook.
AiCure is an AI and advanced data analytics company that monitors patient behavior and enables remote patient engagement in clinical trials. AiCure improves predictability of study timelines, reduces costs and accelerates timelines through remote patient engagement and assessments, including measuring digital biomarkers and real-time monitoring of patient dosing. Founded in 2010 and funded by the National Institutes of Health (NIH) and leading institutional investors, AiCure has more than 65 issued patents and works with global clients in over 30 countries. AiCure is globally recognized and is a recipient of the Scrip Award, AI 100 and Digital Health 150. For more information, please visit www.aicure.com.
Phone: (984) 377-3737
# # #